Renal Cell Carcinoma
Advertisement
Utilizing bevacizumab during breaks in pazopanib treatment can result in lesser toxicity while binding and neutralizing VEGF.
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer.
In the second part of the session, the panel highlights some of the most important recent developments in papillary RCC.
In part one of the session, the panelists dive into an in-depth exploration and debate on the results of SUNNIFORECAST.
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies.
The panel discusses the use of immunotherapy, specifically PD-1 based therapies, in renal cell carcinoma.
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
Disease control was achieved in 84.6% of patients, 4.3% reached a complete response, 52% had partial response.
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville.
Drs. Samantha Armstrong and Karine Tawagi provide updated commentary on STAMPEDE, SunRISe-4, and SUNNIFORECAST trials.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.